Douglas Johnson

February 18, 2026

Patient with melanoma receives tumor-infiltrating lymphocyte therapy

The highly personalized treatment is currently approved for patients with advanced stages of melanoma whose tumors have grown despite immunotherapies and/or targeted therapies.

By Tom Wilemon
November 12, 2025

Eleven Vanderbilt scientists among this year’s ‘highly cited’ researchers

They are among 6,868 scientists worldwide whose papers rank in the top 1% by citations for their fields of research and publication year in the Web of Science Core Collection over the past 11 years.

By Bill Snyder
The Vanderbilt Ingram Cancer Center (Neil Brake/Vanderbilt)
September 10, 2025

Vanderbilt-Ingram Cancer Center names associate directors and new program leaders 

Shared resources at Vanderbilt-Ingram are designed to support and enhance cancer-relevant research and scientific interaction by providing access to cutting-edge technologies and services, as well as scientific expertise.

By Tom Wilemon
(iStock image)
April 10, 2025

Study provides guidance on immunotherapy-related, chronic skin reactions 

Researchers recommended long-term follow-up for patients by dermatologists familiar with cirAEs and consideration of corticosteroid-sparing treatment options.

By Tom Wilemon
November 19, 2024

Eleven Vanderbilt scientists among world’s ‘highly cited’ researchers

The list recognizes both the scientific achievements of individual scientists and “their profound impact on tackling broader societal challenges.”

By Bill Snyder
Mark Denison, MD, and Xiaotao Lu, MS, are among those on a new list of scientists whose papers have been cited the most frequently by other researchers. (photo by Erin O. Smith)
November 15, 2023

Twelve at Vanderbilt are among world’s highly cited researchers

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers.

By Bill Snyder
August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.
By Tom Wilemon
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
By Tom Wilemon
November 17, 2022

Several from VUMC among most highly cited researchers

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.
By Tom Wilemon
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
April 18, 2019

Medical Societies honor multiple Vanderbilt faculty

Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).
By Bill Snyder
October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
By VUMC News and Communications